Compare SURG & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | IVVD |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 437.1M |
| IPO Year | N/A | 2021 |
| Metric | SURG | IVVD |
|---|---|---|
| Price | $0.88 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $9.75 | $8.75 |
| AVG Volume (30 Days) | 143.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $3.78 | $143.48 |
| Revenue Next Year | $113.46 | $25.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.75 | $0.46 |
| 52 Week High | $3.47 | $3.07 |
| Indicator | SURG | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 51.65 |
| Support Level | $0.75 | $1.41 |
| Resistance Level | $0.95 | $2.01 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 56.89 | 57.32 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.